ALK and lung adenocarcinoma: Later on, nivolumab has been approved also for lung adenocarcinoma patients with progression on or after platinum-based chemotherapy; however, patients with EGFR or ALK-1 genomic aberrations should also have had disease progression on FDA-approved therapy for these aberrations prior to receiving nivolumab [8,26].